CMS Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

  Iron IsomaltosideInjection (Monofer®) is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China, providing a better safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Iron Dextran Injection (Cosmofer®)is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the NEML. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, and will generateefficient synergies with the Group’s existing products across its key specialty areas, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive […]

CMS: NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

MG-K10, a long-acting anti-IL-4Rα humanized monoclonal antibody injection, enables once-every-4-weeks dosing (whereas currently marketed drugs targeting the same pathway require dosing once every 2 weeks), which may improve treatment adherence. It is also expected to become the first long-acting anti-IL-4Rα monoclonal antibody to be marketed globally, demonstrating BIC potential. In a Phase III clinical trial in adult patients with moderate-to-severe SAR, MG-K10 has met the primary endpoint, demonstrating significantly superior efficacy compared with the placebo group, with a favorable safety profile. The acceptance of the NDA represents an important milestone for CMS Vision(the ophthalmology business) in expanding its therapeutic focus from ophthalmology into the field of ENT, and also marks another significant milestone in the Group’s R&D progress in the field of type 2 inflammatory diseases.     China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic […]

CMS Included in S&P Global Sustainability Yearbook (China Edition) for the Fourth Consecutive Year

S&P Global, an internationally recognized rating agency, recently released the Sustainability Yearbook (China Edition) 2026. China Medical System (“CMS” or the “Group”) stood out among nearly 1,800 companies and was successfully included for the fourth consecutive year, underscoring the Group’s long-term resilience and comprehensive strengths in sustainable development. （Source：S&P Global）   CMS integrates the United Nations Sustainable Development Goals (“SDGs”) into the Group’s ESG strategy, guided by top-level planning, is driving a more sustainable transformation across the entire value chain. We are committed to improving accessibility and equity in healthcare, and continue to increase R&D investment in innovative medicines and treatments for rare diseases, addressing unmet clinical needs through scientific innovation. At the same time, we remain dedicated to inclusive healthcare, responding to societal needs through concrete actions and fulfilling the responsibilities expected of a pharmaceutical company. We also place strong emphasis on employee development and environmental protection, and steadily advance our responsible practices.   The Group’s […]

Performance Returns to Growth Trajectory丨CMS (867.HK, 8A8.SG) 2025 Annual Performance Report in One Picture

CMS: New Drug for Renal Anaemia Desidustat Tablets Approved in China

Desidustat Tablets are a noveloral HIF-PHI, approved for treating anaemia in non-dialysis adult CKD patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia. The China Phase III clinical trial of the Product has demonstrated positive results: the study met its primary efficacy endpoint. Extension study results demonstrated that the Product can maintain Hb level within the target range over the long term with acceptable safety, while significantly reducing hepcidin levels and ameliorating iron metabolism disorders. The Product will strengthen the Group’s layout in the field of nephrology and synergize with the marketed innovative drug Velphoro for CKD hyperphosphatemia in terms of expert resources and channel networks.   China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been […]

CMS : Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo

On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well […]

CMS’s Self-Developed Innovative Drug INHBE-Targeting Small Nucleic Acid Drug CMS-D008 received IND approval for Overweight/Obesity Indication

CMS-D008 is a novel siRNA therapy administered by subcutaneous injection that targets and inhibits INHBE. By loweringthe level of INHBE and its encoded Activin E protein, it can block Activin E-ALK7 signaling and reduces fat accumulation effectively. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases.   Preclinical studies suggestedthat CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile, demonstrating potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass.   CMS-D008will synergize with CMS-D005, a self-developed, clinical-stage innovative drug (a GLP-1R/GCGR dual agonist), to deliver highly effective weight-loss benefits and long-term maintenance of results, providing patients with a more comprehensive and innovative treatment option.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice […]

CMS Recognized in S&P Global Sustainability Yearbook for Second Consecutive Year

Recently, S&P Global, an internationally authoritative rating agency, has released the Sustainability Yearbook 2026 (the “Yearbook”). China Medical System (“CMS” or the “Group”) has stood out among 9,200 participating companies and successfully secured a place in the Yearbook, with a 2025 Corporate Sustainability Assessment (CSA) score of 66, surpassing 92% of global peers. This marks the second consecutive year that CMS has earned this international honor.   Source: S&P Global   Guided by its long-term ESG strategic objectives, CMS has deeply integrated the concept of sustainable development into its strategic decision-making and daily operations. The Group is driven by the dual engines of in-house R&D and collaborative R&D, continuously enhancing the accessibility and affordability of healthcare services and working to narrow health disparities across different regions and populations. Concurrently, we actively fulfill our corporate social responsibilities, leveraging innovative biotechnology to drive industry advancement and contribute to the sustained improvement of social well-being. Our sustainability performance has also been recognized by multiple authoritative rating agencies: MSCI ESG Rating maintained at “AA”; the Hong Kong […]

CMS: NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

Ruxolitinib phosphate cream, as the first and only targeted drug approved in China for the treatment of vitiligo, marked a key milestone in its expansion into multiple therapeutic areas with the acceptance of its NDA for the additional indication of AD. The NDA has been included in the Priority Review List based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”which is expected to accelerate the Product’s review process for marketing approval.   Ruxolitinib phosphate cream has achieved positive results in the China Phase III clinical trial for AD: At Week 8, 63.0% of subjects achieved IGA 0/1, with ≥2 grades of reduction from baseline (vs. 9.2% for placebo, P < 0.001); 78.0% of subjects achieved EASI 75 (vs. 15.4% for placebo, P < 0.001). Overall, ruxolitinib phosphate cream was safe and well-tolerated.   For AD, Dermavon has developed a comprehensive “treatment […]

CMS Signed An Exclusive Distribution Agreement for the Original Drug Lidoderm® Lidocaine Cataplasms

Lidoderm® Lidocaine Cataplasms was approved for marketing in China in 2024, and its use for postherpetic neuralgia (PHN) treatment has been supported by consensus in clinical practice guidelines both in China and abroad Leveraging the advantages of its original brand, the Product can form in-depth synergy with the Group’s existing products in terms of expert resources and marketing channels; meanwhile, the Group will actively develop diverse marketing models such as new retail, further accelerating the development of the out-of-hospital market   China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 12 February 2026, the Group through subsidiaries of the Company entered into an exclusive distribution agreement (the “Agreement”) with Teikoku Pharma USA, Inc. (“TPU”, a subsidiary of Japan-based Teikoku Seiyaku Co., Ltd (“TSC”), collectively referred to as the “Cooperation Partner”) for Lidoderm® Lidocaine Cataplasms (the “Product”).   In accordance with […]

IND Approval for Self-developed Product: CMS’s Innovative Drug Complement Factor B Inhibitor CMS-D017 is approved for Drug Clinical Trials for Complement – mediated Kidney Disease Indication

CMS-D017 is a novel selective small-molecule inhibitor of complement factor B（CFB）.By targeting and inhibiting CFB, it blocks abnormal activation of the alternative complement pathway, which reduces damage to target tissues and organs caused by the membrane attack complex, and effectively slows the progression of a range of complement dysregulation-related inflammatory responses and autoimmune diseases. CMS-D017 has demonstrated excellent efficacy and safety in preclinical studies. Besides paroxysmal nocturnal hemoglobinuria(which has been approved for drug clinical trials), it is also being developed for clinical use in the treatment of complement-mediated kidney diseases, including IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, C3 glomerulopathy, etc.; providing a potentially better therapeutic alternative for patients. Upon approval for marketing, CMS-D017 will synergize with the marketed innovative drug Velphoro (hyperphosphatemia of Chronic Kidney Disease) and the new drug currently under NDA review, Desidustat Tablets(renal anemia), in expert networks and market resources, collectively elevating the Group’s capabilities in the field of nephrology. […]

IND Approval for Self-developed Product: CMS’s Innovative Drug Complement Factor B Inhibitor CMS-D017 is approved for Drug Clinical Trials for Paroxysmal Nocturnal Hemoglobinuria Indication

CMS-D017 is a novel selective small-molecule inhibitor of complement factor B (CFB). By targeting and inhibiting CFB, it blocks abnormal activation of the alternative complement pathway, which reduces damage to target tissues and organs caused by the membrane attack complex, and effectively slows the progression of a range of complement dysregulation-related inflammatory responses and autoimmune diseases. CMS-D017 has demonstrated excellent efficacy and safety in preclinical studies and is being developed for clinical use in the treatment of paroxysmal nocturnal hemoglobinuria, providing a potentially better therapeutic alternative for patients. Upon approval for marketing, CMS-D017 will synergize with the marketed innovative drug Velphoro (hyperphosphatemia of Chronic Kidney Disease) and the new drug currently under NDA review, Oxemia (renal anemia), in expert networks and market resources, collectively elevating the Group’s capabilities in the field of nephrology.   China Medical System Holdings Limited ( “CMS” or the “Group”) is pleased to announce that innovative drug CMS-D017 […]